RemeGen Future Growth
Future criteria checks 5/6
RemeGen is forecast to grow earnings and revenue by 52.2% and 26.3% per annum respectively. EPS is expected to grow by 53.4% per annum. Return on equity is forecast to be -29.1% in 3 years.
Key information
52.2%
Earnings growth rate
53.4%
EPS growth rate
| Biotechs earnings growth | 39.4% |
| Revenue growth rate | 26.3% |
| Future return on equity | -29.1% |
| Analyst coverage | Good |
| Last updated | 23 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,322 | -434 | -413 | -122 | 15 |
| 12/31/2025 | 2,518 | -893 | -877 | -554 | 16 |
| 12/31/2024 | 1,679 | -1,553 | -1,608 | -1,195 | 14 |
| 6/30/2024 | 1,402 | -1,588 | -2,178 | -1,615 | N/A |
| 3/31/2024 | 1,245 | -1,536 | -2,354 | -1,579 | N/A |
| 12/31/2023 | 1,083 | -1,511 | -2,356 | -1,503 | N/A |
| 9/30/2023 | 972 | -1,341 | -2,150 | -1,295 | N/A |
| 6/30/2023 | 844 | -1,213 | -2,071 | -1,269 | N/A |
| 3/31/2023 | 790 | -1,036 | -2,007 | -1,260 | N/A |
| 12/31/2022 | 772 | -999 | -2,013 | -1,260 | N/A |
| 9/30/2022 | 1,879 | 276 | -894 | -97 | N/A |
| 6/30/2022 | 1,745 | 231 | -609 | 90 | N/A |
| 3/31/2022 | 1,570 | 174 | -474 | 185 | N/A |
| 12/31/2021 | 1,424 | 276 | -354 | 264 | N/A |
| 9/30/2021 | 115 | -912 | -1,483 | -921 | N/A |
| 6/30/2021 | 29 | -892 | -1,493 | -927 | N/A |
| 3/31/2021 | 4 | -783 | -1,326 | -814 | N/A |
| 12/31/2020 | N/A | -698 | -1,141 | -660 | N/A |
| 9/30/2020 | N/A | -588 | -906 | -543 | N/A |
| 6/30/2020 | N/A | -478 | -671 | -427 | N/A |
| 3/31/2020 | N/A | -442 | -487 | -343 | N/A |
| 12/31/2019 | N/A | -430 | -348 | -283 | N/A |
| 12/31/2018 | 11 | -270 | -212 | -128 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688331 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688331 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688331 is expected to become profitable in the next 3 years.
Revenue vs Market: 688331's revenue (26.3% per year) is forecast to grow faster than the CN market (13.1% per year).
High Growth Revenue: 688331's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688331 is forecast to be unprofitable in 3 years.